Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study

Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study

The introduction of vaccination programs against measles, mumps, and rubella (MMR) led to significant global reduction in morbidity and mortality from these diseases. The currently recommended MMR vaccination schedule in the United States of America comprises 2 vaccine doses typically administered a...

Full description

Bibliographic Details
Main Authors: Remon Abu-Elyazeed, William Jennings, Randall Severance, Michael Noss, Adrian Caplanusi, Michael Povey, Ouzama Henry
Format: Article
Language:English
Published: Taylor & Francis Group 2018-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
immunization schedule
immunogenicity
measles-mumps-rubella vaccine
safety
second dose
Online Access:http://dx.doi.org/10.1080/21645515.2018.1489186

Similar Items

Similar Items